Asset Details
Do you wish to reserve the book?
Comparison of 18FDCFPyL and 68GaGa-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of 18FDCFPyL and 68GaGa-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Do you wish to request the book?
Comparison of 18FDCFPyL and 68GaGa-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of 18FDCFPyL and 68GaGa-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
2015
Overview
Purpose
Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [
68
Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production amount, and image resolution. [
18
F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomography (PET) imaging that has been recently introduced. In the current study, we aimed to compare [
68
Ga]Ga-PSMA-HBED-CC and [
18
F]DCFPyL for clinical use in biochemically relapsed prostate cancer.
Procedures
In 14 selected patients with PSA relapse of prostate cancer, [
18
F]DCFPyL PET/X-ray computed tomography (CT) was performed in addition to [
68
Ga]Ga-PSMA-HBED-CC PET/CT. A systematic comparison was carried out between results obtained with both tracers with regard to the number of detected PSMA-positive lesions, the standardized uptake value (SUV)
max
and the lesion to background ratios.
Results
All suspicious lesions identified by [
68
Ga]Ga-PSMA-HBED-CC were also detected with [
18
F]DCFPyL. In three patients, additional lesions were observed using [
18
F]DCFPyL PET/CT. The mean SUV
max
in the concordant [
18
F]DCFPyL PSMA-positive lesions was significantly higher as compared to [
68
Ga]Ga-PSMA-HBED-CC (14.5
vs.
12.2,
p
= 0.028,
n
= 15). The mean tumor to background ratios (
n
= 15) were significantly higher for [
18
F]DCFPyL compared to [
68
Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as reference organs (
p
= 0.006,
p
= 0.002,
p
= 0.008), but no significant differences were found using the liver (
p
= 0.167) or the mediastinum (
p
= 0.363) as reference organs.
Conclusion
[
18
F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [
18
F]DCFPyL represents a highly promising alternative to [
68
Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.
Publisher
Springer US,Springer Nature B.V
Subject
/ Edetic Acid - analogs & derivatives
/ Edetic Acid - pharmacokinetics
/ Edetic Acid - therapeutic use
/ Humans
/ Imaging
/ Lysine - analogs & derivatives
/ Male
/ Medicine
/ Oligopeptides - pharmacokinetics
/ Oligopeptides - therapeutic use
/ Positron-Emission Tomography - methods
/ Prostatic Neoplasms - diagnostic imaging
/ Prostatic Neoplasms - pathology
/ Radiopharmaceuticals - pharmacokinetics
/ Radiopharmaceuticals - therapeutic use
